BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, July 11, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Nurexone's Exopten nabs US orphan designation for acute spinal injury
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Nurexone's Exopten nabs US orphan designation for acute spinal injury
Oct. 31, 2023
Nurexone Biologic Inc.'s regenerative therapy Exopten has been awarded orphan drug designation by the FDA to treat acute spinal cord injury.
BioWorld Science
Regulatory
Neurology/psychiatric
FDA
Orphan drug
